...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: What a joke!!!

Cancun ... again, I would've loved tto hear about tthe partners that are "in discussion" ... Confidentiality Agreements

foundation for success clinically, and ptential markets, are looking more and more established, and closer to "proven"

Agree with SF ... tea leaves say buy out ... but when? ... would have to be soon, for the additional work to get accomplished. Excited about the FDA letter, obviously "breakthrough" status is being pursued, and the worst case "appears" to be a shorter bolt-on(s) with so much "work" already being done (P1, P2, P3) for potential buyers, good safety, additional IP, and patent protections ... 

Who wants this drug the most? When? At what price? What price is acceptable to the investors based on potential and risks?

dyodd

Share
New Message
Please login to post a reply